The mechanism of action of furmonertinib was characterized through ATPase assays, revealing its interaction with ABCB1 and ABCG2,suggesting a potential strategy to overcome resistance in EGFR exon 20ins-mutated cancers. The gene discussed is ABCG2; the disease is cancer.